Athersys Inc. disclosed three pieces of news: a joint venture with Elan plc, a collaboration with Acorda Therapeutics Inc. and the filing of patents covering more than 10,000 gene sequences. Gil Van Bokkelen, president and CEO of Athersys, said the Cleveland-based functional genomics firm has been quietly perfecting its Random Activation for Gene Expression (RAGE) technology, to create cell lines without using the usual recombinant DNA procedures …
No comments:
Post a Comment